Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Cebarc - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Cebarc

Approved

STANDARD

Cebarc

Geofman Pharmaceuticals🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: e4b6039ad5cf0454
Company: Geofman Pharmaceuticals
Type: Standard

Approval Details

Approval Id: e4b6039ad5cf0454
Drug Approval Philippines Name: Cebarc
Product Name: Cebarc
Registration Number: DRP-4341
Brand Name: Cebarc
Generic Name: Cefpodoxime Proxetil
Dosage Form: Film-Coated Tablet
Dosage Strength: 200mg
Manufacturer: Geofman Pharmaceuticals
Importer: Sahar International Trading, Inc.
Distributor: Sahar International Trading, Inc.
Issuance Date: 27 December 2021
Expiry Date: 31 January 2027
Pharmacologic Category: ANTIBACTERIAL (CEPHALOSPORIN)
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

e4b6039ad5cf0454

Type

Standard

Back to Philippines FDA Approvals